Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis-Reference-Cited by-同舟云学术

Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta‐analysis

Published:2021-07-28 Issue: Volume: Page:
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Zhao Qinhua¹,Guo Na²,Chen Jun²,Parks Daniel³,Tian Zhuang⁴^ORCID

Affiliation:

1. Department of Pulmonary Circulation Shanghai Pulmonary HospitalTongji University School of Medicine Shanghai China

2. GlaxoSmithKline Beijing China

3. GlaxoSmithKline Collegeville PA USA

4. Department of Cardiology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13481

Reference57 articles.

1. Pulmonary Arterial Hypertension.NORD (National Organization for Rare Disorders).2017.https://rarediseases.org/rare‐diseases/pulmonary‐arterial‐hypertension/. Accessed 16 July 2020.

2. Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference;Ghofrani HA;Dtsch Med Wochenschr,2010

3. Survival with first‐line bosentan in patients with primary pulmonary hypertension;McLaughlin VV;Eur Respir J,2005

4. Global public health burden of heart failure;Savarese G;Card Fail Rev,2017

5. [Chinese guidelines for the diagnosis and treatment of pulmonary hypertension 2018];Working Group on Pulmonary Vascular Diseases of Chinese Society of Cardiology of Chinese Medical Association;Zhong hua Xin Xue Guan Bing Za Zhi,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the implementation of risk minimization measures for bosentan: a retrospective study;Expert Opinion on Drug Safety;2024-08-22

2. Utilizing phospholipid as an amphiphilic carrier for solid dispersion of ambrisentan: formulation and evaluation;Journal of Dispersion Science and Technology;2024-07-21

3. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential;Drug Discovery Today;2023-11

4. Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension;Expert Review of Pharmacoeconomics & Outcomes Research;2023-07-07

5. Insights into Endothelin Receptors in Pulmonary Hypertension;International Journal of Molecular Sciences;2023-06-16